Albert Bourla· @AlbertBourla · X·· 2026-06-23精选AI 评分62
AI 导读
美国卫生与公众服务部（HHS）宣布启动一项部门范围的临床试验改革计划，旨在减少不必要的障碍、加速研究、扩大患者参与研究的机会，并强化美国生物医学创新生态。该计划涉及FDA、NIH、ARPA-H和ONC等机构，目标是吸引更多临床研究、投资和医学突破回流美国。辉瑞CEO Albert Bourla 对此表示欢迎，认为加快试验启动且不牺牲科学性是正确方向。
推荐理由
HHS 启动临床试验改革计划，读者可了解美国在减少试验壁垒、加速研究方面的政策方向。
正文
Leading in biomedical innovation comes down to one thing. America should be the best place in the world to discover and test new medicines. Faster trial starts, with no compromise on the science, do exactly that. Good to see this progress from @HHSGov.
Today, HHS launched a department-wide effort to restore U.S. leadership in clinical trials by reducing unnecessary barriers, accelerating research, expanding patient access to studies, and strengthening America’s biomedical innovation ecosystem. From FDA and NIH to ARPA-H and ONC, HHS is working to help bring more clinical research, investment, and medical breakthroughs back to the United States. Read More: https://www.hhs.gov/press-room/hhs-launches-clinical-trials-reform-initiative.html在 X 查看被引用的帖子
来源：Albert Bourla · x.com